Leuven, Belgium – May 17, 2018 – JSR Life Sciences (JLS) is pleased to announce that it has completed its capacity expansion for production of its Amsphere™ A3 protein-A chromatography resin in Leuven, Belgium. The new facility has been built to the highest quality standards using state of the art engineering and is adjacent to JSR’s existing European operations, JSR Micro NV.
SOUTH WINDSOR, Conn. and TOKYO - May 14, 2018 - Oxford Performance Materials, Inc. (OPM), a leader in advanced materials science and high performance additive manufacturing (HPAM®), and Tokyo-based JSR Corporation (JSR), a leading materials supplier in a variety of technology driven markets, today announced a partnership to advance OPM’s poly-ether-ketone-ketone (PEKK)-based 3D-printed orthopedic devices and biomedical & dental materials businesses throughout Asia.
Tokyo, Japan – January 30, 2018 – JSR Corporation has been granted an exclusive license for intellectual property from Keio University for the treatment and diagnosis of inflammatory bowel disease (IBD). JSR then granted exclusive licenses of the key intellectual property to BiomX Ltd., a microbiome drug discovery company developing customized phage therapies, to develop and commercialize phage therapies based on the intellectual property.
TOKYO – Dec. 20, 2017 – JSR Life Sciences (JLS) announced today that JSR Corporation has agreed to purchase Crown Bioscience International (TPEx: ticker 6554) at 12 Billion New Taiwan Dollar, a global drug discovery and development services company providing translational platforms to advanced oncology, inflammation, cardiovascular and metabolic disease research. This acquisition marks JSR’s largest life sciences-focused investment to date, extending the company’s portfolio to include industry-leading contract research and development capabilities
JSR Life Sciences, the life-sciences focused division of JSR Corporation, will offer industry partners best-in-class CDMO services by complementing its commercial subsidiary KBI Biopharma with Selexis SA Technologies
Durham, NC - May 23, 2017 - JSR Life Sciences (JLS) today announced that KBI Biopharma (KBI), a subsidiary of JSR Corporation (JSR), is expanding its biopharmaceutical manufacturing capacity and capabilities at both its Durham, North Carolina and Boulder, Colorado facilities. KBI is investing approximately $30M on the two site expansion projects, which will greatly enhance the offerings at each site and are scheduled for completion later this year.